Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

ABSTRACT:

Background

Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and the United States, on the basis of findings from efficacy studies in animals and safety evaluations in healthy humans. Evidence from randomized, controlled trials of safety and efficacy in patients with mpox is lacking.

Methods

We conducted a double-blind, randomized, placebo-controlled trial of tecovirimat in patients with mpox in the Democratic Republic of Congo (DRC). Patients with at least one mpox skin lesion and positive polymerase-chain-reaction results for clade I MPXV were assigned in a 1:1 ratio to receive tecovirimat or placebo. All patients received supportive care. The primary end point was resolution of mpox lesions, measured in number of days after randomi

SUBMITTER: PALM007 Writing Group 

PROVIDER: S-EPMC12158442 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature